Category: finance – Page 119
Regions Financial Corporation has barred its customers from purchasing cryptocurrencies such as bitcoin.
The US-based bank and financial service clarified in its 2018 bank deposit agreement that it reserved the right to “return or decline to pay” for items related to “decentralized, non-fiat virtual currencies, cryptocurrency or another digital currency or money that relies on distributed ledger or blockchain.”
2018 Regions Bank Deposit Agreement pic.twitter.com/mDtEr5T1ep
Read more
“If I can bring forward the defeat of aging even one day, I would have saved the lives of 110,000 people.” – Dr. Aubrey de Grey at EmTech Asia 2019.
The age-old quest for immortality was largely confined to the myths and legends of past civilizations until about just two decades back when telomerase, the active component for the gene that confers immortality to cells was successfully isolated in a science laboratory. That turned the tide on the entire conversation from whether aging could be treated, to how it could be treated.
Since then it has spawned a whole new medical field – ‘healthspan’ – where scientific research is conducted with the aim of extending healthy human lives for as long as hundreds and thousands of years, if not outright immortality. It is not surprising that the intensive research into anti-aging technologies has attracted financial backing from those who are interested in technological progress – the tech community, the likes of Google and even cryptocurrency tycoons such as Ethereum Founder, Vitalik Buterin, who donated $2.4 million worth of ether to the nonprofit foundation SENS Research Foundation, of which Dr Aubrey de Grey is the Chief Science Officer.
Read more
One of the birthplaces of artificial intelligence, MIT, has announced a bold plan to reshape its academic program around the technology. With $1 billion in funding, MIT will create a new college that combines AI, machine learning, and data science with other academic disciplines. It is the largest financial investment in AI by any US academic institution to date.
New school: The new college of computing is being built with $350 million in funding from Stephen A. Schwarzman, the CEO and cofounder of Blackstone, a private equity firm. Schwarzman has already donated billions to other institutions for studying issues related to AI. MIT’s new Stephen A. Schwarzman College of Computing will create 50 new faculty positions and numerous fellowships for graduate students. The school will open next September and will be housed in existing buildings at MIT before moving to its own space, expected in 2022.
Data everywhere: Data and computing are already having a major impact on disciplines like the humanities, and machine learning and AI may have an even bigger one. Rafael Reif, the president of MIT, said in an announcement that the new approach was necessary because of the way computing, data, and AI are “reshaping the world,” and he added that students and researchers will be taught to use AI in their disciplines from first principles, instead of dividing their time between computer science and other departments. “Computing is no longer the domain of the experts alone,” Reif said. “It’s everywhere, and it needs to be understood and mastered by almost everyone.”
Read more
My colleague Conor Sen recently made a bold prediction: Government will be the driver of the U.S. economy in coming decades. The era of Silicon Valley will end, supplanted by the imperatives of fighting climate change and competing with China.
This would be a momentous change. The biggest tech companies — Amazon.com, Apple Inc., Facebook Inc., Google (Alphabet Inc.) and (a bit surprisingly) Microsoft Corp. — have increasingly dominated both the headlines and the U.S. stock market:
Read more
The push for drug treatments for prediabetes takes place in an environment rife with financial conflicts of interest. For years, ethicists have criticized ADA for financial dependence on diabetes drugmakers. In recent years, ADA says, it has received $18 million to $27 million annually from drug companies, including many donations of $500,000 to $1 million per year. The group also gets up to $500,000 annually from each of more than a dozen other firms in the diabetes and prediabetes markets, including makers of consumer and medical products, testing labs, insurance companies, and drug retailers.
A third of Americans are considered prediabetic—but many may be better off without treatment.
Read more
Artificial intelligence and its subset of disciplines—such as machine learning, natural language processing, and computer vision —are seemingly becoming integrated into our daily lives whether we like it or not. What was once sci-fi is now ubiquitous research and development in company and university labs around the world.
Similarly, the startups working on many of these AI technologies have seen their proverbial stock rise. More than 30 of these companies are now valued at over a billion dollars, according to data research firm CB Insights, which itself employs algorithms to provide insights into the tech business world.
Private companies with a billion-dollar valuation were so uncommon not that long ago that they were dubbed unicorns. Now there are 325 of these once-rare creatures, with a combined valuation north of a trillion dollars, as CB Insights maintains a running count of this exclusive Unicorn Club.
The subset of AI startups accounts for about 10 percent of the total membership, growing rapidly in just 4 years from 0 to 32. Last year, an unprecedented 17 AI startups broke the billion-dollar barrier, with 2018 also a record year for venture capital into private US AI companies at $9.3 billion, CB Insights reported.
Join S-Booster 2019!
We will invite space-based business ideas from the Asia and Oceania regions!The Contest facilitates the realization of each business idea through open innovation with Japanese companies, and also provides financial support, business coaching and other assistances. Promoting Win-Win Business Cooperation Between Asia and Japan!
Read more
Samsara Therapeutics has completed a seed financing round in collaboration with Apollo Ventures, a venture capital company and biotech incubator that supports longevity research and treatments for age-related diseases.
Samsara Therapeutics, Inc. (“Samsara,”) a platform biotechnology startup engaged in the discovery and development of compounds that address the primary molecular causes of aging, announced today the closing of a seed financing round. The financing was led by Apollo Ventures, a life sciences venture capital firm and company builder working across Europe and North America.
Additionally, on February 19th, 2019 Nature Communications published a peer-reviewed paper, “The flavonoid 4,4′-dimethoxychalcone promotes autophagy-dependent longevity across species” authored by Samsara’s scientific team [1]. The paper demonstrates the capability of the Samsara platform to identify novel MoA geroprotective small molecules that extend healthy lifespan across species and which are protective in mammalian models of disease.
Read more
